NASDAQ:AGRX - Agile Therapeutics Stock Price, Price Target & More

$2.89 +0.18 (+6.64 %)
(As of 04/24/2018 04:00 PM ET)
Previous Close$2.71
Today's Range$2.68 - $3.00
52-Week Range$1.93 - $5.60
Volume204,011 shs
Average Volume180,251 shs
Market Capitalization$93.50 million
P/E Ratio-2.95
Dividend YieldN/A
Beta2.14

About Agile Therapeutics (NASDAQ:AGRX)

Agile Therapeutics logoAgile Therapeutics, Inc., a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch, which completed Phase III clinical trials. The company is also developing a pipeline of other transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide shorter lighter periods; AG200-ER (SmP), a regimen to allow a woman to extend the length of her cycle, as well as experience shorter and lighter periods; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was founded in 1997 and is headquartered in Princeton, New Jersey.

Receive AGRX News and Ratings via Email

Sign-up to receive the latest news and ratings for AGRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AGRX
CUSIPN/A
Phone609-683-1880

Debt

Debt-to-Equity RatioN/A
Current Ratio2.57%
Quick Ratio2.57%

Price-To-Earnings

Trailing P/E Ratio-2.95
Forward P/E Ratio-4.07
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.06 per share
Price / Book2.73

Profitability

EPS (Most Recent Fiscal Year)($0.91)
Net Income$-28,300,000.00
Net MarginsN/A
Return on Equity-79.38%
Return on Assets-53.19%

Miscellaneous

Employees21
Outstanding Shares34,250,000

How to Become a New Pot Stock Millionaire

Agile Therapeutics (NASDAQ:AGRX) Frequently Asked Questions

What is Agile Therapeutics' stock symbol?

Agile Therapeutics trades on the NASDAQ under the ticker symbol "AGRX."

How were Agile Therapeutics' earnings last quarter?

Agile Therapeutics (NASDAQ:AGRX) issued its quarterly earnings results on Monday, March, 12th. The specialty pharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.23) by $0.05. View Agile Therapeutics' Earnings History.

What price target have analysts set for AGRX?

6 brokerages have issued twelve-month price objectives for Agile Therapeutics' stock. Their forecasts range from $5.00 to $13.00. On average, they anticipate Agile Therapeutics' stock price to reach $9.00 in the next year. View Analyst Ratings for Agile Therapeutics.

What are Wall Street analysts saying about Agile Therapeutics stock?

Here are some recent quotes from research analysts about Agile Therapeutics stock:
  • 1. HC Wainwright analysts commented, "it as Just Another Delay; Reiterate Buy but Lower to $8 Stock Data 12/21/2017 Price $4.76 Exchange NASDAQ Price Target $8.00 52-Week High $6.62 52-Week Low $2.04 Enterprise Value (M) $131.3 Market Cap (M) $163 Shares Outstanding (M) 34.2 3 Month Avg Volume 267,948 Short Interest (M) 0.30 Balance Sheet Metrics Cash (M) $43.8 Total Debt (M) $12.1 Total Cash/Share $1.28 EPS Diluted Full Year – Dec 2016A 2017E 2018E 1Q (0.27) (0.26)A (0.28) 2Q (0.29) (0.26)A (0.26) 3Q (0.27) (0.22)A (0.29) 4Q (0.18) (0.24) (0.32) FY (1.02) (0.98) (1.16) Revenue ($M) Full Year – Dec 2016A 2017E 2018E 1Q 0.0 0.0A 0.0 2Q 0.0 0.0A 0.0 3Q 0.0 0.0A 0.0 4Q 0.0 0.0 0.0 FY 0.0 0.0 0.0 7 6 5 4 3 2 1 DEC- 16 APR- 17 AUG- 17 DEC- 17 20 15 10 5 0 Vol. (mil) Price Twirla Complete Response Letter surprisingly focused on patch adhesion; we believe the issues are readily addressable. The consensus investor Twirla sticking issue has been around the “high” Phase 3 Pearl Index (implied lower efficacy) vs. prior." (12/22/2017)
  • 2. Cantor Fitzgerald analysts commented, "One time when you’re happy to receive a belated Christmas present. The PDUFA date for Twirla is December 26, and we believe it reasonable that an approval will occur around then. We suppose it might be possible that FDA staffers clear their plates before the holiday season. AGRX management has deftly avoided addressing whether labeling discussions have occurred as that would be an indication that FDA approval could be forthcoming." (11/6/2017)

Who are some of Agile Therapeutics' key competitors?

Who are Agile Therapeutics' key executives?

Agile Therapeutics' management team includes the folowing people:
  • Mr. Alfred F. Altomari, Chairman, Chief Exec. Officer and Pres (Age 59)
  • Mr. Scott M. Coiante, CFO & Sr. VP (Age 51)
  • Dr. Elizabeth Ijeoma Onyemelukwe Garner M.D., M.P.H., Chief Medical Officer and Sr. VP (Age 50)
  • Ms. Mary Coleman, Head of Investor Relations & Corp. Communications
  • Mr. Geoffrey P. Gilmore, Gen. Counsel (Age 52)

Has Agile Therapeutics been receiving favorable news coverage?

News headlines about AGRX stock have been trending somewhat positive on Tuesday, Accern reports. The research firm scores the sentiment of news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Agile Therapeutics earned a coverage optimism score of 0.24 on Accern's scale. They also gave news stories about the specialty pharmaceutical company an impact score of 46.05 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

How do I buy shares of Agile Therapeutics?

Shares of AGRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Agile Therapeutics' stock price today?

One share of AGRX stock can currently be purchased for approximately $2.89.

How big of a company is Agile Therapeutics?

Agile Therapeutics has a market capitalization of $93.50 million. The specialty pharmaceutical company earns $-28,300,000.00 in net income (profit) each year or ($0.91) on an earnings per share basis. Agile Therapeutics employs 21 workers across the globe.

How can I contact Agile Therapeutics?

Agile Therapeutics' mailing address is 101 POOR FARM ROAD, PRINCETON NJ, 08540. The specialty pharmaceutical company can be reached via phone at 609-683-1880 or via email at [email protected]


MarketBeat Community Rating for Agile Therapeutics (AGRX)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  246 (Vote Outperform)
Underperform Votes:  126 (Vote Underperform)
Total Votes:  372
MarketBeat's community ratings are surveys of what our community members think about Agile Therapeutics and other stocks. Vote "Outperform" if you believe AGRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGRX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Agile Therapeutics (NASDAQ:AGRX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
6 Wall Street analysts have issued ratings and price targets for Agile Therapeutics in the last 12 months. Their average twelve-month price target is $9.00, suggesting that the stock has a possible upside of 211.42%. The high price target for AGRX is $13.00 and the low price target for AGRX is $5.00. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.672.672.713.00
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $9.00$9.00$9.20$10.20
Price Target Upside: 211.42% upside182.13% upside233.33% upside98.83% upside

Agile Therapeutics (NASDAQ:AGRX) Consensus Price Target History

Price Target History for Agile Therapeutics (NASDAQ:AGRX)

Agile Therapeutics (NASDAQ:AGRX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/14/2018Noble FinancialReiterated RatingBuyHighView Rating Details
3/13/2018HC WainwrightReiterated RatingBuy$8.00HighView Rating Details
12/28/2017Janney Montgomery ScottDowngradeBuy -> NeutralLowView Rating Details
12/26/2017William BlairDowngradeOutperform -> Market PerformHighView Rating Details
12/22/2017Cantor FitzgeraldReiterated RatingBuy$5.00HighView Rating Details
10/18/2017Royal Bank of CanadaReiterated RatingBuy$10.00N/AView Rating Details
3/11/2017FBR & CoSet Price TargetBuy$10.00LowView Rating Details
(Data available from 4/24/2016 forward)

Earnings

Agile Therapeutics (NASDAQ:AGRX) Earnings History and Estimates Chart

Earnings by Quarter for Agile Therapeutics (NASDAQ:AGRX)

Agile Therapeutics (NASDAQ:AGRX) Earnings Estimates

2018 EPS Consensus Estimate: ($0.66)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.19)($0.19)($0.19)
Q2 20181($0.15)($0.15)($0.15)
Q3 20181($0.16)($0.16)($0.16)
Q4 20181($0.16)($0.16)($0.16)

Agile Therapeutics (NASDAQ AGRX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/12/2018Q4 2017($0.23)($0.18)ViewN/AView Earnings Details
11/6/2017Q3 2017($0.25)($0.22)ViewN/AView Earnings Details
7/28/2017Q2 2017($0.28)($0.2590)ViewN/AView Earnings Details
5/8/2017Q1 2017($0.31)($0.26)ViewN/AView Earnings Details
3/8/2017Q4 2016($0.28)($0.29)ViewN/AView Earnings Details
11/7/2016Q3($0.35)($0.27)ViewN/AView Earnings Details
8/8/2016Q2($0.29)($0.29)ViewN/AView Earnings Details
5/9/2016Q1($0.38)($0.27)ViewN/AView Earnings Details
3/9/2016Q4 2015($0.43)($0.17)ViewN/AView Earnings Details
11/9/2015Q3 2015($0.42)($0.42)ViewN/AView Earnings Details
8/13/2015Q2 2015($0.37)($0.38)ViewN/AView Earnings Details
5/12/2015Q1 2015($0.35)($0.35)ViewN/AView Earnings Details
3/26/2015Q4 2014($0.40)($0.37)ViewN/AView Earnings Details
11/13/2014Q3 2014($0.50)($0.34)ViewN/AView Earnings Details
8/14/2014Q2 2014($0.43)($0.46)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Agile Therapeutics (NASDAQ:AGRX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Agile Therapeutics (NASDAQ AGRX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.10%
Institutional Ownership Percentage: 71.06%
Insider Trading History for Agile Therapeutics (NASDAQ:AGRX)
Institutional Ownership by Quarter for Agile Therapeutics (NASDAQ:AGRX)

Agile Therapeutics (NASDAQ AGRX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/25/2017Alfred AltomariChairmanBuy10,000$3.34$33,400.00161,587View SEC Filing  
8/25/2017Renee SelmanInsiderBuy7,250$3.35$24,287.5060,583View SEC Filing  
5/11/2017Alfred AltomariChairmanBuy10,000$3.51$35,100.00151,587View SEC Filing  
5/11/2017Renee SelmanInsiderBuy53,333$3.68$196,265.4453,333View SEC Filing  
1/27/2016Jay MoorinMajor ShareholderBuy393,700$6.35$2,499,995.00View SEC Filing  
6/2/2015Alfred AltomariCEOBuy2,500$8.73$21,825.00View SEC Filing  
1/23/2015Jay MoorinMajor ShareholderBuy811,966$5.85$4,750,001.10View SEC Filing  
5/29/2014Care Capital Iii LlcMajor ShareholderBuy500,000$6.00$3,000,000.00View SEC Filing  
5/23/2014Andrew N SchiffDirectorBuy1,333,333$6.00$7,999,998.00View SEC Filing  
5/22/2014Ab InvestorMajor ShareholderBuy1,000,000$6.00$6,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Agile Therapeutics (NASDAQ AGRX) News Headlines

Source:
DateHeadline
Agile Therapeutics (AGRX) Given Consensus Rating of "Hold" by AnalystsAgile Therapeutics (AGRX) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - April 19 at 5:45 AM
Agile Therapeutics (AGRX) Earns Buy Rating from Analysts at HC WainwrightAgile Therapeutics (AGRX) Earns Buy Rating from Analysts at HC Wainwright
www.americanbankingnews.com - April 17 at 12:04 AM
Agile Therapeutics (AGRX) Expected to Announce Earnings of -$0.19 Per ShareAgile Therapeutics (AGRX) Expected to Announce Earnings of -$0.19 Per Share
www.americanbankingnews.com - April 16 at 1:10 PM
Noble Financial Reaffirms "Buy" Rating for Agile Therapeutics (AGRX)Noble Financial Reaffirms "Buy" Rating for Agile Therapeutics (AGRX)
www.americanbankingnews.com - April 15 at 9:45 AM
HC Wainwright Reaffirms Buy Rating for Agile Therapeutics (AGRX)HC Wainwright Reaffirms Buy Rating for Agile Therapeutics (AGRX)
www.americanbankingnews.com - April 8 at 3:15 PM
Cantor Fitzgerald Comments on Agile Therapeutics FY2019 Earnings (AGRX)Cantor Fitzgerald Comments on Agile Therapeutics' FY2019 Earnings (AGRX)
www.americanbankingnews.com - April 6 at 8:23 AM
Agile Therapeutics (AGRX) Expected to Post Earnings of -$0.20 Per ShareAgile Therapeutics (AGRX) Expected to Post Earnings of -$0.20 Per Share
www.americanbankingnews.com - March 30 at 3:10 PM
What Should Investors Know About Agile Therapeutics Inc’s (NASDAQ:AGRX) Long Term Outlook?What Should Investors Know About Agile Therapeutics Inc’s (NASDAQ:AGRX) Long Term Outlook?
finance.yahoo.com - March 28 at 5:19 PM
Pre-Market Technical Scan on Generic Drugs Equities -- Adamas Pharma, Agile Therapeutics, Catalent, and Diplomat PharmacyPre-Market Technical Scan on Generic Drugs Equities -- Adamas Pharma, Agile Therapeutics, Catalent, and Diplomat Pharmacy
www.prnewswire.com - March 26 at 8:22 AM
Agile Therapeutics (AGRX) Given Consensus Recommendation of "Hold" by AnalystsAgile Therapeutics (AGRX) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - March 25 at 5:32 AM
New Research: Key Drivers of Growth for At Home Group, Griffon, Mitek, J & J Snack Foods, Lindsay, and Agile Therapeutics — Factors of Influence, Major Initiatives and Sustained ProductionNew Research: Key Drivers of Growth for At Home Group, Griffon, Mitek, J & J Snack Foods, Lindsay, and Agile Therapeutics — Factors of Influence, Major Initiatives and Sustained Production
finance.yahoo.com - March 23 at 8:18 AM
Is Agile Therapeutics Inc’s (NASDAQ:AGRX) Balance Sheet A Threat To Its Future?Is Agile Therapeutics Inc’s (NASDAQ:AGRX) Balance Sheet A Threat To Its Future?
finance.yahoo.com - March 20 at 5:18 PM
Agile Therapeutics (AGRX) Receives "Buy" Rating from Noble FinancialAgile Therapeutics (AGRX) Receives "Buy" Rating from Noble Financial
www.americanbankingnews.com - March 15 at 6:44 PM
Agile Therapeutics Inc (AGRX) Forecasted to Earn Q1 2018 Earnings of ($0.19) Per ShareAgile Therapeutics Inc (AGRX) Forecasted to Earn Q1 2018 Earnings of ($0.19) Per Share
www.americanbankingnews.com - March 15 at 7:36 AM
Abstract on AG200-15 (Twirla®) Accepted for Presentation at the APhA 2018 Annual Meeting & Exposition - GlobeNewswire (press release)Abstract on AG200-15 (Twirla®) Accepted for Presentation at the APhA 2018 Annual Meeting & Exposition - GlobeNewswire (press release)
globenewswire.com - March 14 at 8:31 AM
Abstract on AG200-15 (Twirla®) Accepted for Presentation at the APhA 2018 Annual Meeting & ExpositionAbstract on AG200-15 (Twirla®) Accepted for Presentation at the APhA 2018 Annual Meeting & Exposition
finance.yahoo.com - March 14 at 8:31 AM
-$0.28 EPS Expected for Agile Therapeutics Inc (AGRX) This Quarter-$0.28 EPS Expected for Agile Therapeutics Inc (AGRX) This Quarter
www.americanbankingnews.com - March 13 at 1:57 PM
HC Wainwright Reaffirms "Buy" Rating for Agile Therapeutics (AGRX)HC Wainwright Reaffirms "Buy" Rating for Agile Therapeutics (AGRX)
www.americanbankingnews.com - March 13 at 1:38 PM
Agile Therapeutics Reports Fourth Quarter and Full Year 2017 ... - NasdaqAgile Therapeutics Reports Fourth Quarter and Full Year 2017 ... - Nasdaq
www.nasdaq.com - March 13 at 8:25 AM
Agile Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results - GlobeNewswire (press release)Agile Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - March 13 at 8:25 AM
Agile Therapeutics Inc (AGRX) Sees Significant Decline in Short InterestAgile Therapeutics Inc (AGRX) Sees Significant Decline in Short Interest
www.americanbankingnews.com - March 13 at 1:08 AM
Agile Therapeutics Reports Fourth Quarter and Full Year 2017 Financial ResultsAgile Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - March 12 at 6:40 PM
Agile Therapeutics Inc (AGRX) Given Consensus Rating of "Buy" by AnalystsAgile Therapeutics Inc (AGRX) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - February 28 at 5:36 AM
Agile Therapeutics Inc (AGRX) Given Average Recommendation of "Buy" by BrokeragesAgile Therapeutics Inc (AGRX) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - February 3 at 5:28 AM
New Research Coverage Highlights Oracle, General Dynamics, Agile Therapeutics, Fidelity Southern, Syros Pharmaceuticals, and MSA Safety Incorporated — Consolidated Revenues, Company Growth, and Expectations for 2018New Research Coverage Highlights Oracle, General Dynamics, Agile Therapeutics, Fidelity Southern, Syros Pharmaceuticals, and MSA Safety Incorporated — Consolidated Revenues, Company Growth, and Expectations for 2018
finance.yahoo.com - January 24 at 8:06 AM
Technical Perspectives on Generic Drugs Stocks -- Fibrocell Science, Galectin Therapeutics, Agile Therapeutics, and ... - PR Newswire (press release)Technical Perspectives on Generic Drugs Stocks -- Fibrocell Science, Galectin Therapeutics, Agile Therapeutics, and ... - PR Newswire (press release)
www.prnewswire.com - January 20 at 7:25 AM
Agile Therapeutics Inc (AGRX) Receives Average Recommendation of "Buy" from AnalystsAgile Therapeutics Inc (AGRX) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - January 9 at 7:58 AM
Zacks: Brokerages Anticipate Agile Therapeutics Inc (AGRX) to Announce -$0.24 EPSZacks: Brokerages Anticipate Agile Therapeutics Inc (AGRX) to Announce -$0.24 EPS
www.americanbankingnews.com - January 4 at 7:28 PM
Agile Therapeutics (AGRX) Rating Reiterated by Noble FinancialAgile Therapeutics (AGRX) Rating Reiterated by Noble Financial
www.americanbankingnews.com - December 29 at 5:04 PM
Agile Therapeutics (AGRX) Stock Rating Lowered by Janney Montgomery ScottAgile Therapeutics (AGRX) Stock Rating Lowered by Janney Montgomery Scott
www.americanbankingnews.com - December 29 at 5:04 PM
HC Wainwright Analysts Give Agile Therapeutics (AGRX) a $8.00 Price TargetHC Wainwright Analysts Give Agile Therapeutics (AGRX) a $8.00 Price Target
www.americanbankingnews.com - December 29 at 3:34 PM
FY2017 EPS Estimates for Agile Therapeutics Inc (AGRX) Decreased by Cantor FitzgeraldFY2017 EPS Estimates for Agile Therapeutics Inc (AGRX) Decreased by Cantor Fitzgerald
www.americanbankingnews.com - December 29 at 7:56 AM
Agile Therapeutics: Sell-Off Post CRL Makes It Worth A Look - Seeking AlphaAgile Therapeutics: Sell-Off Post CRL Makes It Worth A Look - Seeking Alpha
seekingalpha.com - December 27 at 9:58 AM
Critical Contrast: Relypsa (RLYP) and Agile Therapeutics (AGRX)Critical Contrast: Relypsa (RLYP) and Agile Therapeutics (AGRX)
www.americanbankingnews.com - December 26 at 8:01 PM
Agile Therapeutics (AGRX) Downgraded to Market Perform at William BlairAgile Therapeutics (AGRX) Downgraded to Market Perform at William Blair
www.americanbankingnews.com - December 26 at 7:36 AM
Agile Therapeutics (AGRX) "Buy" Rating Reaffirmed at Cantor FitzgeraldAgile Therapeutics' (AGRX) "Buy" Rating Reaffirmed at Cantor Fitzgerald
www.americanbankingnews.com - December 25 at 1:32 PM
Agile Therapeutics (AGRX) Stock Rating Reaffirmed by Noble FinancialAgile Therapeutics (AGRX) Stock Rating Reaffirmed by Noble Financial
www.americanbankingnews.com - December 25 at 12:38 PM
Agile Therapeutics plunges toward record low after FDA rejects contraceptive patchs NDA - MarketWatchAgile Therapeutics plunges toward record low after FDA rejects contraceptive patch's NDA - MarketWatch
www.marketwatch.com - December 23 at 3:46 PM
Agile Therapeutics, Inc. Receives a Complete Response Letter from the FDA for Twirla® (AG200-15) for the Prevention ... - GlobeNewswire (press release)Agile Therapeutics, Inc. Receives a Complete Response Letter from the FDA for Twirla® (AG200-15) for the Prevention ... - GlobeNewswire (press release)
globenewswire.com - December 23 at 3:46 PM
Agile Therapeutics (AGRX) Receives CRL from FDA for Twirla for Prevention of PregnancyAgile Therapeutics (AGRX) Receives CRL from FDA for Twirla for Prevention of Pregnancy
www.streetinsider.com - December 22 at 8:42 PM
Agile Therapeutics, Inc. Receives a Complete Response Letter from the FDA for Twirla® (AG200-15) for the Prevention of PregnancyAgile Therapeutics, Inc. Receives a Complete Response Letter from the FDA for Twirla® (AG200-15) for the Prevention of Pregnancy
finance.yahoo.com - December 22 at 8:42 PM
Agile Therapeutics plunges toward record low after FDA rejects contraceptive patchs NDAAgile Therapeutics plunges toward record low after FDA rejects contraceptive patch's NDA
finance.yahoo.com - December 22 at 8:42 PM
Agile Therapeutics (AGRX) PT Set at $8.00 by HC WainwrightAgile Therapeutics (AGRX) PT Set at $8.00 by HC Wainwright
www.americanbankingnews.com - December 22 at 3:58 PM
Mid-Day Market Update: Ignyta Surges Following Merger Deal With Roche; Agile Therapeutics Shares Plunge - NasdaqMid-Day Market Update: Ignyta Surges Following Merger Deal With Roche; Agile Therapeutics Shares Plunge - Nasdaq
www.nasdaq.com - December 22 at 3:40 PM
Agile Therapeutics (AGRX) Receives CRL from FDA for Twirla for Prevention of Pregnancy - StreetInsider.comAgile Therapeutics (AGRX) Receives CRL from FDA for Twirla for Prevention of Pregnancy - StreetInsider.com
www.streetinsider.com - December 22 at 3:40 PM
Who Are The Largest Shareholders In Agile Therapeutics Inc (NASDAQ:AGRX)?Who Are The Largest Shareholders In Agile Therapeutics Inc (NASDAQ:AGRX)?
finance.yahoo.com - December 21 at 3:24 PM
Agile Therapeutics, Inc. (AGRX) Receives Average Rating of "Buy" from AnalystsAgile Therapeutics, Inc. (AGRX) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - December 15 at 5:52 AM
Head to Head Survey: Agile Therapeutics (AGRX) vs. Celsion (CLSN)Head to Head Survey: Agile Therapeutics (AGRX) vs. Celsion (CLSN)
www.americanbankingnews.com - December 13 at 5:12 AM
Is It Too Late To Buy Agile Therapeutics Inc (AGRX)?Is It Too Late To Buy Agile Therapeutics Inc (AGRX)?
finance.yahoo.com - December 1 at 3:24 PM
Agile Therapeutics, Inc. (AGRX) Stock Rating Reaffirmed by Cantor FitzgeraldAgile Therapeutics, Inc. (AGRX) Stock Rating Reaffirmed by Cantor Fitzgerald
www.americanbankingnews.com - November 20 at 6:46 PM

SEC Filings

Agile Therapeutics (NASDAQ:AGRX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Agile Therapeutics (NASDAQ:AGRX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Agile Therapeutics (NASDAQ AGRX) Stock Chart for Tuesday, April, 24, 2018

Loading chart…

This page was last updated on 4/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.